SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Ticker SymbolSIBN
Company nameSI-BONE Inc
IPO dateOct 17, 2018
CEOMs. Laura A. Francis
Number of employees349
Security typeOrdinary Share
Fiscal year-endOct 17
Address471 El Camino Real, Suite 101
CitySANTA CLARA
Stock exchangeMoscow Interbank Currency Exchange (MICEX)
CountryUnited States of America
Postal code95050
Phone14082070700
Websitehttps://si-bone.com/
Ticker SymbolSIBN
IPO dateOct 17, 2018
CEOMs. Laura A. Francis
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data